Tromsø, Norway, 2. April 2019 – Biotec Pharmacon (OSE: Biotec) announced today that its subsidiary, ArcticZymes, has been granted €254k as part of a collaborative project on the development of novel enzymes for synthetic biology. The project proposal was developed in collaboration with the University of Tromsø and Danish company, Legomics, has been positively evaluated by the Eurostars programme. ArcticZymes …
Biotec Pharmacon’s subsidiary, ArcticZymes launches its first ligase enzyme
Tromsø, Norway, 7 February 2019 – Biotec Pharmacon’s (OSE: Biotec) subsidiary ArcticZymes adds its first ligase enzyme, T4 DNA ligase, to its portfolio. T4 DNA ligase, the most widely used enzyme in the ligase family, works by joining DNA fragments together. It is used in the development of kits and products serving the In Vitro Diagnostic (IVD) and molecular research …
Biotec Pharmacon awarded grant from Research Council of Norway to develop next-generation wound product
Tromsø, Norway, 04 February 2019 – Biotec Pharmacon (OSE: Biotec) announces today that its subsidiary Biotec BetaGlucans has been awarded up to NOK 8 million in a grant by the Research Council of Norway for a project titled “Bioactive wound healing dressing with beta-glucan for treatment of hard-to-heal wounds”. The project is to be supported over 4 years. The grant …
Biotec Pharmacon finalises Post Market study on Woulgan®
Tromsø, Norway, 29 January 2019 – Biotec Pharmacon’s (OSE: Biotec) has announced that its subsidiary, Biotec BetaGlucans, has finalised treatment in a UK Post Market Clinical Follow-up (PMCF) study on its wound care gel, Woulgan®, in diabetic foot ulcer patients. Biotec BetaGlucans filed an application to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in June 2018 to finalise …